Kera-X ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 168 | Ehlers-Danlos syndrome | 1 |
168. Ehlers-Danlos syndrome
Clinical trials : 8 / Drugs : 17 - (DrugBank : 9) / Drug target genes : 9 - Drug target pathways : 55
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01307527 (ClinicalTrials.gov) | November 2008 | 1/3/2011 | Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI | Brittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6 | Drug: Riboflavin;Device: Kera-X | Hadassah Medical Organization | NULL | Enrolling by invitation | 18 Years | N/A | Both | 1 | N/A | Israel |